Stock 300391 CHANGJIANG PHARMACEUTICAL GROUP CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Changjiang Pharmaceutical Group Co., Ltd.

Equities

300391

CNE100001XN8

Pharmaceuticals

End-of-day quote Shenzhen S.E.
Other stock markets
 06:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
3.97 CNY -4.57% Intraday chart for Changjiang Pharmaceutical Group Co., Ltd. +3.93% -48.71%
Apr. 09 Yichang Hec Changjiang Pharmaceutical Updates on Possible Merger with Sunshine Lake Pharma MT
Apr. 01 Yichang Hec Changjiang Pharmaceutical's Net Profit Surges in 2023 as Revenue Jumps MT

Valuation

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Capitalization 1 2,602 2,270 2,547 4,299 5,325 3,416
Enterprise Value (EV) 1 2,653 2,187 2,372 5,151 6,168 4,418
P/E ratio 35.4 x 22 x -3.81 x 170 x 108 x -147 x
Yield 0.15% 0.51% - - - -
Capitalization / Revenue 3.5 x 2.58 x 3.51 x 3.54 x 2.25 x 2.11 x
EV / Revenue 3.57 x 2.48 x 3.27 x 4.24 x 2.61 x 2.73 x
EV / EBITDA 23.2 x 13.9 x -58.2 x 43.2 x 21.6 x 24.7 x
EV / FCF 9.9 x -8.02 x 16.9 x 21.2 x -15 x -14.4 x
FCF Yield 10.1% -12.5% 5.91% 4.72% -6.67% -6.92%
Price to Book 2.78 x 1.58 x 3.36 x 5.53 x 6.44 x 4.27 x
Nbr of stocks (in thousands) 297,308 350,336 350,336 350,336 350,336 350,336
Reference price 2 8.753 6.480 7.270 12.27 15.20 9.750
Announcement Date 4/22/18 3/29/19 4/27/20 4/27/21 4/27/22 4/27/23
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net sales 1 744.2 881 725.3 1,215 2,362 1,615
EBITDA 1 114.3 156.8 -40.72 119.4 285.2 178.9
EBIT 1 77.98 116.1 -81.4 78.76 228.6 75.5
Operating Margin 10.48% 13.17% -11.22% 6.49% 9.68% 4.67%
Earnings before Tax (EBT) 1 69.49 116.5 -680.2 58.41 158.3 71.83
Net income 1 69.72 102 -669.7 25.32 49.1 -23.27
Net margin 9.37% 11.58% -92.33% 2.08% 2.08% -1.44%
EPS 2 0.2476 0.2949 -1.910 0.0723 0.1402 -0.0664
Free Cash Flow 1 268 -272.6 140.2 243.3 -411.3 -305.8
FCF margin 36.02% -30.94% 19.32% 20.04% -17.41% -18.93%
FCF Conversion (EBITDA) 234.6% - - 203.87% - -
FCF Conversion (Net income) 384.48% - - 961.02% - -
Dividend per Share 2 0.0133 0.0333 - - - -
Announcement Date 4/22/18 3/29/19 4/27/20 4/27/21 4/27/22 4/27/23
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net Debt 1 51.1 - - 852 843 1,002
Net Cash position 1 - 83.1 175 - - -
Leverage (Debt/EBITDA) 0.4469 x - - 7.141 x 2.957 x 5.601 x
Free Cash Flow 1 268 -273 140 243 -411 -306
ROE (net income / shareholders' equity) 10.4% 8.42% -61.6% 6.02% 10.4% 2.72%
ROA (Net income/ Total Assets) 3.59% 3.58% -2.82% 1.59% 3.21% 1.21%
Assets 1 1,943 2,850 23,742 1,596 1,529 -1,922
Book Value Per Share 2 3.140 4.100 2.160 2.220 2.360 2.290
Cash Flow per Share 2 0.8600 1.020 1.170 0.4000 0.3100 0.0500
Capex 1 4.05 8.84 5.24 18.8 142 51.5
Capex / Sales 0.54% 1% 0.72% 1.55% 6.02% 3.19%
Announcement Date 4/22/18 3/29/19 4/27/20 4/27/21 4/27/22 4/27/23
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
CHANGJIANG PHARMACEUTICAL GROUP CO., LTD. Stock Changjiang Pharmaceutical Group Co., Ltd.
-48.71% 192M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 300391 Stock
  4. Financials Changjiang Pharmaceutical Group Co., Ltd.